Clinical Trial Update: Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating dinutuximab beta in combination with zoledronic acid and low-dose interleukin-2 in leiomyosarcoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leiomyosarcoma

Drugs mentioned

• Interleukin-2 (IL-2) (interleukin-2)
• Zoledronic acid (Zoledronic acid)
• dinutuximab beta (dinutuximab beta)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Leiomyosarcoma | Phase 2 | Status: COMPLETED